Taro Pharmaceutical Industries L (NYSE: TARO) has reported E.P.S. of $0.40 for its fourth fiscal quarter (ending March 31) versus $0.18 for the same period a year ago. For the latest four quarters through March 31, E.P.S. were $1.43 compared to $0.68 a year ago.
Recent Price Action
Taro Pharmaceutical Industries L (NYSE: TARO) stock closed at $42.42 on 5/20/24 after a slight gain of 0.3%. However, exceptionally low trading volume at 47% of normal accompanied the advance. Relative to the market the stock has been strong over the last nine months and is unchanged during the last week.
Current PriceTarget Research Rating
TARO is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Taro Pharmaceutical Industries L has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Taro Pharmaceutical Industries L has a neutral Appreciation Score of 50 and a slightly positive Power Rating of 66, with the High Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment